INTRODUCTION

Amid an uncertain market in 2025, funding trends for MedTech companies are exceeding expectations, with Q2 funding continuing a positive trajectory compared to 2024, showing a 33% increase. This upward trend prompts critical questions about how service providers can optimize their strategies in this evolving landscape. Drawing directly from Zapyrus market intelligence data, this report illuminates key MedTech funding trends from 2025 to address these questions, offering insights crucial for MedTech business development and strategic market analysis.

This report offers crucial MedTech market insights by revealing a relatively healthy MedTech market, with funding actively flowing to both early- and late-stage companies. Key findings indicate a notable concentration of funding in fewer hands, meaning companies receiving investment are securing significantly larger sums than in 2024. Furthermore, we observe a disproportionately higher investment into the EMEA region compared to North America and APAC, signaling a potential shift in regional focus for investors. Despite these shifts, the startup market remains robust, and US early-stage grant funding through SBIR continues to track consistently with previous years, suggesting stable opportunities.

For sales and marketing teams at service provider companies, these insights are highly actionable. The increased funding concentration necessitates more targeted outreach efforts. The shift in regional investment highlights emerging opportunities in the European market while signaling increased competition in the US. By understanding the average company lifecycle milestones post-funding such as patent awards, study initiations, and regulatory approvals, service providers can strategically time their outreach and tailor their service pitches to align with companies' immediate needs. This report underscores the critical need for data-driven market intelligence tools to identify and act on these nuanced opportunities, a gap that Zapyrus MedTech intelligence is specifically designed to fill, offering comprehensive and actionable insights for effective engagement.

A Look at Total Funding

Observing the MedTech funding trends over the past four quarters of 2024, it's clear that 2025 funding is following a similar pattern, albeit at a higher volume. The year began with a substantial funding volume of $17.71 billion in Q1, experiencing a dip to $9.94 billion in Q2. This trend aligns with 2024, suggesting an expectation for higher funding volumes in Q3 compared to Q2. While broader venture capital platforms like Crunchbase or PitchBook offer general market insights, Zapyrus provides the granular, MedTech-specific data that sales and marketing teams at service providers need to pinpoint and act on opportunities within this specialized sector.

Despite the overall increase in total MedTech investment, the actual number of funded companies has decreased so far in 2025 compared to 2024. This indicates that the companies securing funding are receiving relatively larger sums up 54% in Q1 and 38% in Q2 compared to 2024. This concentration of funding in fewer hands, influenced by several large financings from public companies, suggests that service providers offering MedTech consulting or MedTech market entry strategies need to adopt a more targeted approach in their outreach efforts. This aligns with broader industry reports on deal size increases in venture capital.

Understanding Investment Types

The first half of 2025 (H1 2025) reveals a broad distribution of investments across various funding series. As anticipated, the number of companies receiving Seed and Series A investments are relatively higher than Series B+, despite the lower total funding. This pattern signifies a substantial increase in average deal size as companies progress into Series B+. It also suggests that MedTech companies are becoming more capital efficient.

An examination of the top-funded companies in Q2 2025 by investment series provides further insight into specific companies.

This overview highlights a potential weakening in the R&D expansion phase of companies in 2025, as suggested by the relative decrease in Series C funding volume compared to Series B. This, too, warrants observation in upcoming quarters to confirm if it's a true trend.

A striking observation from the top-funded companies is their headquarters location: 71% are in EMEA (Europe, Middle East, and Africa), 14% in North America (NA), and 14% in APAC (Asia-Pacific). This distribution is particularly interesting because it does not align with the overall distribution of global MedTech companies. The relative investment in EMEA is 22% higher on the basis of the number of MedTech companies, suggesting a disproportionately higher investment in this region. This could be a significant indicator that market turbulence in the US is redirecting investment towards Europe. For service providers, this signals potential new opportunities in the European market as well as increased competition in the US market. The ability to accurately identify these MedTech market opportunities will become increasingly vital, a gap that Zapyrus MedTech intelligence can help address.

Funding by Company Size

Total funding (in USD) to MedTech companies in Q2 of 2025 by Company Size. Startup = 1 - 100, Mid-market = 101 - 1,000, Large = 1,001+.

Analyzing funding data by company size offers further insights into what kinds of companies are receiving the most investment. The trend observed in Q2 is interesting as we see a dip in funding to Mid-market size companies (101 - 1,000 employees) compared to Q1 2025. This does suggest that Mid-market companies may stabilize their financing through sales and revenue instead. Overall, this indicates that the Startup market is strong and certainly not deficient with opportunities relative to larger companies. This trend can also be observed in general startup funding reports.

Trends in US Grant Funding

There are valid concerns that early-stage funding is being impacted in the US due to policy changes. However, a previous blog released by Zapyrus showed that the trend in NIH funding in 2025 thus far was on-trend with that observed in previous years. Q2 data reinforces this conclusion for SBIR (Small Business Innovation Research) funding.

The NIH funding to MedTech companies in 2025 continues to track on-trend with the past 3 years. This suggests that policy changes have not, or not yet, impacted this type of MedTech grant funding to early-stage companies. Therefore, service providers to US-based companies can maintain a level of confidence that there will be opportunities in this market for these early-stage companies who will very likely need assistance in navigating design, clinical, regulatory, and commercial stages in these uncertain times. For more on SBIR grant opportunities, the official SBIR.gov website is a primary resource.

Understanding the Company Lifecycle After Funding

While understanding MedTech funding trends is valuable, it's equally important to grasp what comes next for funded companies. An analysis of historical data in Zapyrus was performed to create an average timeline for early-stage funded companies, illustrating a typical company lifecycle:

For startup companies receiving early-stage funding (Grant, Seed, or Series A), the next milestone to follow a funding event is, on average, a first patent awarded, which is generally expected to occur about 7.2 months later. Along with this, for companies which have products requiring clinical studies, the first study initiation generally happens around this time as well. This puts these milestones in Q4 2025 for early-stage funded companies in Q2 2025. Following these milestones, the average timeline for first regulatory approval then tends to occur about 12.2 months after funding, landing in Q2 2026. And finally, some of the later-stage milestones, including commercial launch and study closeout, happen another 4-6 months after that, anticipated around Q4 2026. The caveat is that this is a generalization of medical technology development timeline as this is not segmenting risk classification devices which could shorten or lengthen this timeline.

This kind of analysis helps to paint an overall picture of what to expect for a MedTech company’s progression and can serve as general guidance for service providers around when to begin pitching certain services. These timelines are incredibly difficult to accurately predict. 

This is why Zapyrus launched Zapyrus Intelligence, a powerful proprietary AI opportunity scoring system that predicts the likelihood of MedTech companies reaching their next milestones before they start. The first score launched is the Clinical Opportunity Score which informs on likelihood of clinical study initiation in the coming 6 months. This represents just one of the tailored benefits Zapyrus users have access to for identifying and actioning on opportunities. Our clients across CRO services, preclinical, design & development regulatory, and CDMOs are finding great initial success in faster account scoring allowing focus on high value opportunities to convert.

CONCLUSION:

Overall, the trends in 2025 thus far would indicate a relatively healthy MedTech market, with funding flowing to both early- and late-stage companies. As the year evolves, we may continue to see shifts in regional MedTech investment, which affect how service providers approach MedTech companies in these regions.

In order to stay on top of these shifts and be the first to take action on them, service providers will need to increasingly rely on data-driven market intelligence tools to make decisions.

Zapyrus is the only sales & marketing tool that is MedTech specific and actionable purposely designed for the MedTech service providers. Unlike broader platforms, Zapyrus provides the focused, deep insights that enable sales and marketing teams at service provider companies to precisely identify and engage the right MedTech companies at the right time. If you’ve found yourself interested in the insight provided in this report and how you can have access to more MedTech market insights, book a demo to see Zapyrus in action today!

🚀 Whether you're selling regulatory strategy, clinical support, manufacturing, or commercialization services, Zapyrus helps you prioritize the right accounts, act on real signals, and close more deals, faster.

👉 Book a demo with Zapyrus today and turn market chaos into measurable growth.

Thank you for reading this report!

Subscribe to “the BUZZ” to be updated on the MedTech industry trends, sales best practices, upcoming conferences/events in MedTech, interviews with founders and more.